Drug
Heplisav
Heplisav: highest development phase Phase 3, developed by Dynavax Technologies. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Dynavax Technologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| HEPLISAV NCT01195246 | Phase 3 | End Stage Renal Disease |
| HEPLISAV NCT02117934 | Phase 3 | Healthy |
| HEPLISAV NCT00511095 | Phase 2 | Hepatitis B |
| HEPLISAV NCT01999699 | Phase 1 | Hepatitis B |
Latest
No recent events.
Follow Heplisav on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.